Course Information

Release date: November 7, 2025
Expiration date: November 7, 2026
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a significant health burden, affecting about 25% to 30% of the 28.9 million US adults with chronic rhinosinusitis. These patients face increased risk of comorbidities, frequent need for functional endoscopic sinus surgery (FESS), and overreliance on oral corticosteroids (OCS). Moreover, many continue to have poor symptom control and impaired quality of life, often reporting poor sleep, depression, and social withdrawal despite standard care.

Join expert faculty in this interactive, case-based activity and work through real-world patient challenges, exploring key decision points. Along the way, faculty will provide guidance and insight on patient assessment, current evidence on the safety and efficacy of available treatments, strategies for individualized treatment selection, and approaches to overcoming barriers to optimal biologic use.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of otolaryngic allergists, otolaryngologists, allergists, and specialty advanced practice clinicians involved in the management of CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Implement both subjective and objective measures in the evaluation and assessment of patients with CRSwNP
Select treatments for patients with CRSwNP based on individual patient characteristics and available evidence
Implement strategies to overcome barriers to the optimal use of biologics in the treatment of patients with CRSwNP

Faculty Information and Disclosures

FACULTY

Christine Franzese, MD

Professor of Clinical Otolaryngology

Director of Allergy

Department of Otolaryngology – Head and Neck Surgery

University of Missouri

Columbia, Missouri 

Michael Platt, MD, MSc

Associate Professor and Residency Director

Director of Rhinology and Endoscopic Skull Base Surgery

Department of Otolaryngology – Head and Neck Surgery

Chobanian and Avedesian School of Medicine

Boston University

Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Christine Franzese, MD

Research Support: AstraZeneca, Eli Lilly, GlaxoSmithKline, Lyra, Regeneron, Sanofi, Upstream Bio

Speakers Bureaus: AstraZeneca, GlaxoSmithKline, Optinose, Regeneron, Sanofi

Michael Platt, MD, MSc

Consulting Fees: AstraZeneca, GI Reviewers, GlaxoSmithKline, Sanofi

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 7, 2025 through November 7, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 7, 2025Expiration date: November 7, 2026Estimated time to complete activity: 45 minutes

CRSwNP in Focus: Evidence-Based Strategies for Assessment and Treatment Decision-Making